Samumed
Toggle navigation
Company
Culture
Team
Technology
Pipeline
Publications
Media
Español
Health Through
Regeneration
LEARN MORE
Samumed's Osteoarthritis Research Selected for an Oral Presentation at a Gordon Research Conference
Samumed Successfully Completed 52-week Phase 2 Study for Treatment of Osteoarthritis of the Knee
Samumed Receives Orphan Drug Designation from FDA for SM04646 as a Treatment for Idiopathic Pulmonary Fibrosis (IPF)